HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $100 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 85.4%

Neg 0% Neu 85.4% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $100 price target.